Hostname: page-component-cd9895bd7-dzt6s Total loading time: 0 Render date: 2024-12-22T23:54:08.414Z Has data issue: false hasContentIssue false

Addressing the Emergence and Impact of Multidrug-Resistant Gram-Negative Organisms: A Critical Focus for the Next Decade

Published online by Cambridge University Press:  10 May 2016

Ebbing Lautenbach*
Affiliation:
Division of Infectious Diseases, Department of Medicine, Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Eli N. Perencevich
Affiliation:
Division of General Internal Medicine, Department of Internal Medicine, Carver College of Medicine, University of Iowa, and Center for Comprehensive Access and Delivery Research and Evaluation, Iowa City Veterans Administration Health Care System, Iowa City, Iowa
*
Center for Clinical Epidemiology and Biostatistics, 825 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104-6021 ([email protected])

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Introduction
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Cosgrove, SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006;42(suppl 2):S82S89.Google Scholar
2. Roberts, RR, Hota, B, Ahmad, I, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis 2009;49(8):11751184.Google Scholar
3. Hidron, AI, Edwards, JR, Patel, J, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infect Control Hosp Epidemiol 2008;29(11):9961011.Google Scholar
4. Rhomberg, PR, Jones, RN. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999–2008). Diagnost Microbiol Infect Dis 2009;65(4):414426.Google Scholar
5. Lautenbach, E, Synnestvedt, M, Weiner, MG, et al. Epidemiology and impact of imipenem resistance in Acinetobacter baumannii . Infect Control Hosp Epidemiol 2009;30(12):11861192.Google Scholar
6. Lautenbach, E, Synnestvedt, M, Weiner, MG, et al. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect Control Hosp Epidemiol 2010;31(1):4753.Google Scholar
7. Schwaber, MJ, Klarfeld-Lidji, S, Navon-Venezia, S, Schwartz, D, Leavitt, A, Carmeli, Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008;52(3):10281033.Google Scholar
8. Patel, G, Huprikar, S, Factor, SH, Jenkins, SG, Calfee, DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008;29(12):10991106.Google Scholar
9. Ben-David, D, Kordevani, R, Keller, N, et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect 2012;18(1):5460.CrossRefGoogle ScholarPubMed
10. Banerjee, R, Johnston, B, Lohse, C, Porter, SB, Clabots, C, Johnson, JR. Escherichia coli sequence type 131 is a dominant, antimicrobial-resistant clonal group associated with healthcare and elderly hosts. Infect Control Hosp Epidemiol 2013;34(4):361369.Google Scholar
11. Daly, MW, Riddle, DJ, Ledeboer, NA, Dunne, WM, Ritchie, DJ. Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae . Pharmacotherapy 2007;27(7):10521057.Google Scholar
12. Anthony, KB, Fishman, NO, Linkin, DR, Gasink, LB, Edelstein, PH, Lautenbach, E. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 2008;46(4):567570.Google Scholar
13. Falagas, ME, Karageorgopoulos, DE, Nordmann, P. Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzingenzymes. Future Microbiol 2011;6(6):653666.Google Scholar
14. Satlin, MJ, Kubin, CJ, Blumenthal, JS, et al. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother 2011;55(12):58935899.Google Scholar
15. Infectious Diseases Society of America (IDSA). Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 2011;52(suppl 5):397428.Google Scholar
16. Kwon, S, Schweizer, ML, Perencevich, EN. National Institute of Allergy and Infectious Disease (NIAID) funding for studies of hospital-associated bacterial pathogens: are funds proportionate to burden of disease? Antimicrob Resist Infect Control 2012;1(1):5.Google Scholar
17. Han, JH, Maslow, J, Han, X, et al. Risk factors for the development of gastrointestinal colonization with fluoroquinolone-resistant Escherichia coli in residents of long-term care facilities. J Infect Dis 2014;209(3):420425.Google Scholar
18. Furuno, JP, Hebden, JN, Standiford, HC, et al. Prevalence of methicillin-resistant Staphylococcus aureus and Acinetobacter baumannii in a long-term acute care facility. Am J Infect Control 2008;36(7):468471.Google Scholar